EUCTR2012-004024-38-DE进行中（未招募）不适用
A 4-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of diclofenac diethylamine 2.32% gel for the relief of signs and symptoms in patients with knee osteoarthritis
ovartis Consumer Health S.A.0 个研究点开始时间: 2013年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must give written informed consent before any assessment is performed.
- •At screening visit
- •2. Male or female = 50 years old;
- •3. Symptomatic OA of one or both knees, according to American College of Rheumatology (ACR) criteria, diagnosed at least 6 months previously;
- •4. Pain in either knee originates in the knee (not referred pain from other sites, such as hip or back) and no other cause of pain than knee OA;
- •5. Have used oral NSAIDs or COXIBs for the knee OA pain (including aspirin if = 500 mg and used in this indication), at least one dose per day, for not less than 10 days out of the 14 days preceding the screening visit and also within the 24 hours preceding the screening visit;
- •6. Be able to tolerate rescue medication with only 500 mg paracetamol (APAP) taken in doses of 1 2 tablets up to a maximum of 6 tablets (3 grams) per day for the duration of the study;
- •7. If female of childbearing potential (not postmenopausal for>1 year or surgically sterilized), agree to maintain an effective method of contraception throughout the study.
- •At baseline visit
- •8. Negative pregnancy test if female of child-bearing potential;
- •9. POM in one knee (which is designated as the target knee) higher by = 25 mm vs. the other knee;
- •10. POM in the target knee increased by = 10 mm vs. screening visit;
- •11. POM = 50 mm in the target knee;
- •12. Pain was predominant in the target knee during the entire screening period and for 6 months preceding the screening visit;
- •13. Radiograph of the target knee, no more than one year old, showing evidence of OA, Kellgren-Lawrence grade 1-3;
- •14. No current hip or back pain
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 126
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 126
排除标准
- •1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
- •2.History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- •3. Long QT syndrome or QTc>450 ms for males and >470 ms for females at screening or baseline
- •4.History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of evidence of local recurrence or metastases
- •5.Pregnant or nursing women
- •6.If a female of childbearing potential (i.e. not>1 year postmenopausal or surgically sterilized), agree to maintain an effective method of contraception throughout the study.
- •Particular exclusion criteria
- •7.Partial or total replacement of either knee joint, past or planned/expected during study
- •8.OA of the knee due to other underlying conditions, such as gout, chondrocalcinosis, hemochromatosis, joint infections, neuropathia, or severe traumatic joint damage (common risk factors, such as obesity and past meniscectomy or ligament rupture and repair are allowed)
- •9.History of systemic inflammatory (autoimmune) disease (rheumatoid arthritis, systemic psoriasis, systemic lupus erythematosus, systemic sclerosis) or laboratory values indicative of such disease with subsequent diagnosis by a physician
- •10.Fibromyalgia within the previous year
- •11.Allergy or asthma to diclofenac, APAP, aspirin, other NSAIDs, or any of the ingredients in the gel (isopropyl alcohol, propylene glycol or butylhydroxytoluene) or any other contraindication for study drug or rescue medication
- •12.Skin lesions or wounds in the affected area
- •13.Evidence of active peptic ulceration within the previous year or history of gastrointestinal bleeds
- •14.Clinically significant medical disease, which would compromise the subject’s welfare or confound the study results, such as severe/uncontrolled renal, hepatic, hematological, endocrine, cardiovascular, and neurological diseases within the previous year
- •15.Use of any of the following treatments prior to the screening visit or between screening and baseline visit:
- •i)any topical analgesic or anti-inflammatory treatment on either knee within the previous month,
- •ii)any intra-articular or peri-articular procedures or injections in either knee within the previous 3 months,
- •iii)any systemic treatment with corticosteroids within the previous 6 weeks (topical treatments with corticosteroids not related to either knee are permitted),
- •iv)any chondroprotectant or disease-modifying OA drugs, such as glucosamine or chondroitin sulfate, unless dose was stable over the previous month and will be maintained throughout the study,
- •v)opiates, muscle relaxants or tranquilizers within the previous month except stable low doses of antidepressants, anxiolytics, and sleeping aids taken at bedtime, present at the screening visit and maintained throughout the study,
- •vi) any systemic anti-inflammatory or analgesic drugs at screening if 5 times their elimination half-time exceeds 7 days (i.e., if half-life >33.6 h),
- •vii) anticoagulants such as warfarin or heparin in the preceding week or antiaggregants within the previous month other than aspirin at stable low doses started at least one month before randomization and kept at a constant dose throughout the study,
- •viii) any other investigational drugs within the previous month;
- •16. Any of the following prior to the baseline visit:
研究者
相似试验
进行中（未招募）
不适用
A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertensioMedDRA version: 8.0Level: LLTClassification code 10031161OsteoarthritisEUCTR2005-003286-17-FIovartis Pharma Services AG1,020
进行中（未招募）
不适用
A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertensioMedDRA version: 8.0Level: LLTClassification code 10031161OsteoarthritisEUCTR2005-003286-17-SEovartis Pharma Services AG1,020
进行中（未招募）
1 期
A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertensioOsteoarthritisEUCTR2005-003286-17-GBovartis Pharma Services AG
进行中（未招募）
不适用
A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertensioMedDRA version: 8.0Level: LLTClassification code 10031161OsteoarthritisEUCTR2005-003286-17-ATovartis Pharma Services AG65
进行中（未招募）
不适用
A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in an improved 24-hour blood pressure profile compared to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertensioMedDRA version: 8.0Level: LLTClassification code 10031161OsteoarthritisEUCTR2005-003286-17-DEovartis Pharma Services AG1,050